AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Resources For Cancer Patients
Navigating cancer care can be a complex and overwhelming journey. This section shares stories from other patients and medically reviewed resources from cancer doctors to help you understand different types of cancer. Explore this page to stay informed and supported throughout your care journey.
Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment
By Andrew H. Ko, MD
A new oral RAS(ON) inhibitor, daraxonrasib, nearly doubled overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial.
Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment
By Andrew H. Ko, MD
A new oral RAS(ON) inhibitor, daraxonrasib, nearly doubled overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial.
Daraxonrasib and the RAS(ON) Revolution in Pancreatic Cancer Treatment
By Andrew H. Ko, MD
A new oral RAS(ON) inhibitor, daraxonrasib, nearly doubled overall survival compared with chemotherapy in patients with previously treated metastatic pancreatic cancer in the Phase 3 RASolute 302 trial.
How to Treat Mantle Cell Lymphoma in 2026
By Yucai Wang, MD, PhD
Frontline treatment for mantle cell lymphoma (MCL) is no longer a simple, one-size-fits-all algorithm split by transplant eligibility
How to Treat Mantle Cell Lymphoma in 2026
By Yucai Wang, MD, PhD
Frontline treatment for mantle cell lymphoma (MCL) is no longer a simple, one-size-fits-all algorithm split by transplant eligibility
How to Treat Mantle Cell Lymphoma in 2026
By Yucai Wang, MD, PhD
Frontline treatment for mantle cell lymphoma (MCL) is no longer a simple, one-size-fits-all algorithm split by transplant eligibility
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.
Rethinking Frontline Therapy in Leukemia: Why Lower-Intensity Regimens Are Gaining Ground in AML, MDS, and ALL
By Anand Ashwin Patel, MD
Newer data are steadily narrowing the population that benefits from intensive chemotherapy in acute leukemia.
Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Permission to Pause Treatment
By Peter Silberstein, MD
Four developments from this year's ASCO meeting reshape decision-making across the prostate cancer spectrum, from the operating room to the metastatic setting.
Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Permission to Pause Treatment
By Peter Silberstein, MD
Four developments from this year's ASCO meeting reshape decision-making across the prostate cancer spectrum, from the operating room to the metastatic setting.
Prostate Cancer in 2026: Perioperative Therapy, Biomarker-Driven Combinations, and Permission to Pause Treatment
By Peter Silberstein, MD
Four developments from this year's ASCO meeting reshape decision-making across the prostate cancer spectrum, from the operating room to the metastatic setting.
CAR-T Cell Therapy for Large B-Cell Lymphoma: Who, When, and Where to Deliver It
By Chenyu Lin, MD
CAR-T cell therapy for large B-cell lymphoma is expanding through broader patient eligibility, earlier treatment, head-to-head trials, and remote monitoring.
CAR-T Cell Therapy for Large B-Cell Lymphoma: Who, When, and Where to Deliver It
By Chenyu Lin, MD
CAR-T cell therapy for large B-cell lymphoma is expanding through broader patient eligibility, earlier treatment, head-to-head trials, and remote monitoring.
CAR-T Cell Therapy for Large B-Cell Lymphoma: Who, When, and Where to Deliver It
By Chenyu Lin, MD
CAR-T cell therapy for large B-cell lymphoma is expanding through broader patient eligibility, earlier treatment, head-to-head trials, and remote monitoring.
Alcohol and Cancer: How Much Risk Does Drinking Add?
By The Cancer News Team
Most people know that tobacco causes cancer, but far fewer know that alcohol does, too. In the United States alone, alcohol contributes to nearly 100,000 new cancer diagnoses and approximately 20,000 cancer deaths every year.
Alcohol and Cancer: How Much Risk Does Drinking Add?
By The Cancer News Team
Most people know that tobacco causes cancer, but far fewer know that alcohol does, too. In the United States alone, alcohol contributes to nearly 100,000 new cancer diagnoses and approximately 20,000 cancer deaths every year.
Alcohol and Cancer: How Much Risk Does Drinking Add?
By The Cancer News Team
Most people know that tobacco causes cancer, but far fewer know that alcohol does, too. In the United States alone, alcohol contributes to nearly 100,000 new cancer diagnoses and approximately 20,000 cancer deaths every year.
World Lung Cancer Day 2026: What Lung Cancer Doctors Want You to Know
By Ariana Sutherland, MSc
On World Lung Cancer Day 2026, oncologists weigh in on screening stigma, smoking cessation, and the treatment advances giving patients reason for cautious optimism. Here's what they want you to know.
World Lung Cancer Day 2026: What Lung Cancer Doctors Want You to Know
By Ariana Sutherland, MSc
On World Lung Cancer Day 2026, oncologists weigh in on screening stigma, smoking cessation, and the treatment advances giving patients reason for cautious optimism. Here's what they want you to know.
World Lung Cancer Day 2026: What Lung Cancer Doctors Want You to Know
By Ariana Sutherland, MSc
On World Lung Cancer Day 2026, oncologists weigh in on screening stigma, smoking cessation, and the treatment advances giving patients reason for cautious optimism. Here's what they want you to know.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
Recognizing and Treating Triple M Syndrome: A Checkpoint Inhibitor Toxicity Case
By Katherine Hill, PharmD, BCOP
Triple M syndrome, the co-occurrence of myocarditis, myasthenia gravis, and myositis, is a rare but potentially fatal complication of immune checkpoint inhibitor (ICI) therapy, with reported fatality rates approaching 30-50%.
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed
AML Updates From ASCO 2026: Menin Inhibitor Maintenance and Two Targeted Triplets
By Clark Alsfeld, MD
Three abstracts from the 2026 ASCO Annual Meeting speak to where acute myeloid leukemia (AML) treatment is headed
New Prostate Cancer Data From ASCO 2026: PROTEUS, TALAPRO-3, and Treatment Holidays
By Dalia Hammoud, MD
Together, PROTEUS, TALAPRO-3, and A-DREAM speak to a broader shift in the field: treatment intensity is increasingly being matched to individual risk and response, rather than applied uniformly.
New Prostate Cancer Data From ASCO 2026: PROTEUS, TALAPRO-3, and Treatment Holidays
By Dalia Hammoud, MD
Together, PROTEUS, TALAPRO-3, and A-DREAM speak to a broader shift in the field: treatment intensity is increasingly being matched to individual risk and response, rather than applied uniformly.
New Prostate Cancer Data From ASCO 2026: PROTEUS, TALAPRO-3, and Treatment Holidays
By Dalia Hammoud, MD
Together, PROTEUS, TALAPRO-3, and A-DREAM speak to a broader shift in the field: treatment intensity is increasingly being matched to individual risk and response, rather than applied uniformly.